| Name | Title | Contact Details |
|---|---|---|
Antonio Taylor |
Vice President of Infrastructure, Security | Profile |
Joel Schwalbe |
Chief Information Officer | Profile |
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Velocigo provides custom IT solutions and managed services for businesses across industries. Learn why you should rely on our team as your IT consultant.
We work with you to resolve your outstanding accounts and get your finances back on track.
Since 1996, we’ve provided a complete range of information technology services and solutions to business. We do all the geeky stuff you think of when you think of computers and we get things working reliably. Then we go the extra mile by helping you ...
Effortless Construction Job Site Monitoring And ReportingBUILDING THE FUTURE, TOGETHERSiteKick is the most comprehensive site monitoring and reporting solution for managing construction site activities 0:000:00 Keeping your jobsites rolling smoothly is...